Chunli Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chunli Zhang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Enrun Zheng
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing 100191, China
21 shared publications - Hui Liu
Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
21 shared publications - Lin He
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing 100191, China
21 shared publications - Luyang Sun
Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Peking University, Beijing, China.
21 shared publications - Mengyu Yang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University International Cancer Institute, Peking University Health Science Center, Beijing, China. 2
21 shared publications - Pengyu Xiang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University International Cancer Institute, Peking University Health Science Center, Beijing, China. 2
21 shared publications
Latest Publications
- 27 August 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (11) , 1201-1213
CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8+ T cells
- 27 August 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (11) , 1201-1213
CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8+ T cells
- Open Access
- 17 December 2024
- Published by Wiley in Molecular Carcinogenesis
- Vol. 64 (3) , 502-512
mRNA m5C Alteration in Azacitidine Demethylation Treatment of Acute Myeloid Leukemia
The DNA demethylating therapy with azacitidine (AZA) is a promising therapeutic strategy for elderly patients with acute myeloid leukemia (AML). AZA primarily inhibits DNA methylation, promotes cell differentiation and apoptosis in AML. However, as a cytosine nucleoside analog, AZA also has the potential to be incorporated into RNA molecules. To assess the impact of AZA on RNA m5C methylation during demethylating therapy, we conducted Nanopore direct‐RNA sequencing on samples from three AML patients pre and after demethylating therapy, as well as on HL‐60 cells pretreated with AZA. We performed an integrated analysis of the transcriptome and the m5C methylome, contrasting the states of complete remission with those of active disease (AML). Our results revealed an extensive demethylation effect at the RNA level attributable to AZA and found that mRNA m5C modification may play a pivotal role in the progression of AML. Additionally, S100P was identified as a biomarker with significant prognostic implications. We also conducted a conjoint analysis of the transcriptome and the m5C methylome of the full‐length transcripts, uncovering several dysregulated mRNA isoforms. Collectively, our findings indicate that mRNA m5C methylation is implicated during AML progression, and AZA exhibits an overall suppressive effect on this process.
- 17 December 2024
- Published by Wiley in Molecular Carcinogenesis
- Vol. 64 (3) , 502-512
Open AccessmRNA m5C Alteration in Azacitidine Demethylation Treatment of Acute Myeloid Leukemia
The DNA demethylating therapy with azacitidine (AZA) is a promising therapeutic strategy for elderly patients with acute myeloid leukemia (AML). AZA primarily inhibits DNA methylation, promotes cell differentiation and apoptosis in AML. However, as a cytosine nucleoside analog, AZA also has the potential to be incorporated into RNA molecules. To assess the impact of AZA on RNA m5C methylation during demethylating therapy, we conducted Nanopore direct‐RNA sequencing on samples from three AML patients pre and after demethylating therapy, as well as on HL‐60 cells pretreated with AZA. We performed an integrated analysis of the transcriptome and the m5C methylome, contrasting the states of complete remission with those of active disease (AML). Our results revealed an extensive demethylation effect at the RNA level attributable to AZA and found that mRNA m5C modification may play a pivotal role in the progression of AML. Additionally, S100P was identified as a biomarker with significant prognostic implications. We also conducted a conjoint analysis of the transcriptome and the m5C methylome of the full‐length transcripts, uncovering several dysregulated mRNA isoforms. Collectively, our findings indicate that mRNA m5C methylation is implicated during AML progression, and AZA exhibits an overall suppressive effect on this process.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S3. Cytogenetic Abnormality-associated Gene Expression and Clonal Evolution in MM Cells.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S3. Cytogenetic Abnormality-associated Gene Expression and Clonal Evolution in MM Cells.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S4. Quality Control of the Public scRNA-seq Dataset and Clustering of the Cells within the MM Microenvironment.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S4. Quality Control of the Public scRNA-seq Dataset and Clustering of the Cells within the MM Microenvironment.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S5. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S5. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S2. Clustering of the Cells within the MM Microenvironment.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S2. Clustering of the Cells within the MM Microenvironment.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S4. Quality Control of the Public scRNA-seq Dataset and Clustering of the Cells within the MM Microenvironment.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S4. Quality Control of the Public scRNA-seq Dataset and Clustering of the Cells within the MM Microenvironment.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S1. Quality Control of the scRNA-seq Data.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S1. Quality Control of the scRNA-seq Data.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S7. BCMA CAR-T Therapy Attenuates BAFF/GALECTIN/MK Pathway-mediated Immunosuppression and Activates MIF Pathway-mediated Anti-MM Immunity.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Figure S7. BCMA CAR-T Therapy Attenuates BAFF/GALECTIN/MK Pathway-mediated Immunosuppression and Activates MIF Pathway-mediated Anti-MM Immunity.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Table S1. Baseline Characteristics of MM Patients before BCMA CAR-T Therapy.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Supplementary Table S1. Baseline Characteristics of MM Patients before BCMA CAR-T Therapy.